Compare Pfizer with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs AUROBINDO PHARMA - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER AUROBINDO PHARMA PFIZER/
AUROBINDO PHARMA
 
P/E (TTM) x 37.1 16.7 222.2% View Chart
P/BV x 6.3 3.1 206.2% View Chart
Dividend Yield % 0.5 0.3 157.4%  

Financials

 PFIZER   AUROBINDO PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-19
AUROBINDO PHARMA
Mar-19
PFIZER/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,840830 462.7%   
Low Rs2,080527 394.6%   
Sales per share (Unadj.) Rs455.0333.9 136.3%  
Earnings per share (Unadj.) Rs93.840.4 232.4%  
Cash flow per share (Unadj.) Rs109.451.8 211.3%  
Dividends per share (Unadj.) Rs22.502.50 900.0%  
Dividend yield (eoy) %0.80.4 206.3%  
Book value per share (Unadj.) Rs658.2237.1 277.6%  
Shares outstanding (eoy) m45.75585.91 7.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.52.0 320.1%   
Avg P/E ratio x31.616.8 187.7%  
P/CF ratio (eoy) x27.113.1 206.4%  
Price / Book Value ratio x4.52.9 157.1%  
Dividend payout %24.06.2 387.3%   
Avg Mkt Cap Rs m135,420397,569 34.1%   
No. of employees `0002.617.9 14.7%   
Total wages/salary Rs m3,23825,849 12.5%   
Avg. sales/employee Rs Th7,911.410,956.9 72.2%   
Avg. wages/employee Rs Th1,230.91,447.7 85.0%   
Avg. net profit/employee Rs Th1,630.71,324.3 123.1%   
INCOME DATA
Net Sales Rs m20,815195,636 10.6%  
Other income Rs m1,6741,553 107.8%   
Total revenues Rs m22,489197,189 11.4%   
Gross profit Rs m5,71239,519 14.5%  
Depreciation Rs m7146,680 10.7%   
Interest Rs m732,626 2.8%   
Profit before tax Rs m6,59931,767 20.8%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m2,3097,269 31.8%   
Profit after tax Rs m4,29123,645 18.1%  
Gross profit margin %27.420.2 135.8%  
Effective tax rate %35.022.9 152.9%   
Net profit margin %20.612.1 170.5%  
BALANCE SHEET DATA
Current assets Rs m27,167153,645 17.7%   
Current liabilities Rs m8,917120,429 7.4%   
Net working cap to sales %87.717.0 516.4%  
Current ratio x3.01.3 238.8%  
Inventory Days Days68135 50.2%  
Debtors Days Days3064 47.3%  
Net fixed assets Rs m8,862103,909 8.5%   
Share capital Rs m458586 78.1%   
"Free" reserves Rs m29,656138,322 21.4%   
Net worth Rs m30,113138,908 21.7%   
Long term debt Rs m251,800 1.4%   
Total assets Rs m39,400264,544 14.9%  
Interest coverage x91.513.1 698.8%   
Debt to equity ratio x00 6.4%  
Sales to assets ratio x0.50.7 71.4%   
Return on assets %11.19.9 111.5%  
Return on equity %14.217.0 83.7%  
Return on capital %22.123.8 92.9%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m42897,316 0.4%   
Fx outflow Rs m78640,589 1.9%   
Net fx Rs m-35856,727 -0.6%   
CASH FLOW
From Operations Rs m97816,220 6.0%  
From Investments Rs m351-28,768 -1.2%  
From Financial Activity Rs m-1,09919,191 -5.7%  
Net Cashflow Rs m2316,656 3.5%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 8.0 94.3%  
FIIs % 4.9 27.7 17.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.2 232.4%  
Shareholders   85,207 69,601 122.4%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   UNICHEM LAB  SUN PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 260 Points Lower; Finance and Banking Stocks Witness Huge Selling(Closing)

Indian share markets witnessed negative trading activity today and ended their trading session lower.

Related Views on News

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

Protect Your Wealth from Fund Managers(Fast Profits Daily)

May 14, 2020

Do you know how much you are paying in fees to your mutual fund? In this video I'll share with you my views.

Covid-19 Offers a Rare Opportunity to Own This Brand Leader(Profit Hunter)

May 12, 2020

Covid-19 has compounded uncertainties in investing but this smallcap company is strong enough to survive and even emerge stronger.

Of India's 20 Trillion Stimulus Package and the Swoosh Index for a Swoosh Recovery(Profit Hunter)

May 13, 2020

For India's rapid economic recovery, hopping on to the Swoosh index is a must.

How Commodity Prices Tell You When Stocks Will Go Up(Fast Profits Daily)

May 20, 2020

Commodity prices often provide clues to big moves in stock markets. In today's video, I'll explain this link.

Why Buffet - and you - should study Quantum Liquid Fund(The Honest Truth)

May 14, 2020

Ajit Dayal on how Quantum Liquid Fund and Warren Buffett have similar investing styles.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


May 22, 2020 (Close)

TRACK PFIZER

PFIZER - STRIDES PHARMA SCIENCE COMPARISON

COMPARE PFIZER WITH

MARKET STATS